Phase II Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Cidofovir Topical Gel for the Treatment of Patients with Human Papillomavirus Infection

Genital condylomata acuminata are nonmalignant human papillomavirus (HPV)-induced tumors in which HPV types 6 and 11 are most commonly found. Usual treatments for condylomata acuminata are nonspecific and are based on the destruction or removal of infected tissue. These procedures are often painful...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2001-09, Vol.33 (5), p.597-602
Main Authors: Snoeck, R., Bossens, M., Parent, D., Delaere, B., Degreef, H., Van Ranst, M., Noël, J. C., Wulfsohn, M. S., Rooney, J. F., Jaffe, H. S., De Clercq, E.
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Antivirals
Biological and medical sciences
Condylomata acuminata
Cytosine - analogs & derivatives
Cytosine - therapeutic use
Female
Gels
Genitalia
Humans
Infections
Lesions
Major Articles
Male
Medical sciences
Middle Aged
Organophosphonates
Organophosphorus Compounds - therapeutic use
Papilloma
Papillomaviridae - drug effects
Papillomaviridae - isolation & purification
Papillomavirus Infections - drug therapy
Pharmacology. Drug treatments
Placebos
Risk Factors
Treatment Outcome
Tumor Virus Infections - drug therapy
Viruses
Warts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genital condylomata acuminata are nonmalignant human papillomavirus (HPV)-induced tumors in which HPV types 6 and 11 are most commonly found. Usual treatments for condylomata acuminata are nonspecific and are based on the destruction or removal of infected tissue. These procedures are often painful and are characterized by a high relapse rate. We report here what is to our knowledge the first double-blind, placebo-controlled study of the use of cidofovir, a nucleotide analogue, for the treatment of genital papillomavirus infections. Thirty patients were enrolled in the study; 19 received cidofovir, and 11 received placebo. The median number of warts and the median baseline wart area were comparable for both groups. Nine (47%) of 19 patients in the cidofovir group had a complete response (total healing), compared with 0 of the patients in the placebo group (P = .006). None of the patients in the cidofovir group experienced progression of the disease, compared with 5 (45%) of 11 patients in the placebo group. The side effects recorded for both groups were comparable.
ISSN:1058-4838
1537-6591
DOI:10.1086/322593